Skip to Content

New Treatments for Atopic Dermatitis to Come

Stephan Weidinger discusses the data on an OX40 ligand inhibitor that aims to target immune activation in atopic dermatitis (AD), which plays a crucial role in the proliferation and survival of antigen-specific T-cells. He also mentions other drugs in development, including one targeting OX40 receptors, IL-2 for stimulating T regulatory cells, and long-term safety and efficacy data for established biologics.

Stephan Weidinger

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top